

SYNTHESIS, CHARACTERIZATION ANTI OXIDANT ACTIVITY OF NOVEL 1,5 BENZOTHAIEPINES FROM CHALCONES OF 1-(2,4-DIFLUOROPHENYL) ETHANONE PRECURSOR

Ch. M. M. Prasada Rao*¹ Y. Ranganayakulu² and A. Vasu Babu³

¹Dept. of Pharm. Chemistry, QIS College of Pharmacy, Vengamukka Palem, Ongole-523272.

²Dept. of Basic sciences and humanity, chalapathi inisttiute of engineering and techonlogy, Lam, Guntur-522034.

³Department of Chemistry, QIS College of engineering and technology, Autonomous, Vengamukka Palem, Ongole-523272.

*Corresponding Author: Ch. M. M. Prasada Rao

Dept. of Pharm. Chemistry, QIS College of Pharmacy, Vengamukka Palem, Ongole-523272.

Article Received on 22/04/2017

Article Revised on 11/05/2017

Article Accepted on 02/06/2017

ABSTRACT


1,5 benzothiazepines heterocyclic ring system having the diverse pharmacological activities. The present work focus on synthesis of novel benzothiazepines molecules by condensation of 1-(2',4'-difluorophenyl)-3-(4"-methylphenyl)-2-propen-1-one derivatives and O-amino thiophenol in the presence piperidine and glacial acetic acid. The structures of compounds were confirmed by spectral analysis using IR, 1HNMR and Mass analysis. The biological evolution of compounds were performed for anti oxidant activity by using DPPH reagent method using standard ascorbic acid.

KEYWORDS: Chalcones, 1,5 benzothiazepines, DPPH reagent, anti oxidant activity.


INTRODUCTION


The benzothiazepines^[1-6] (1 and 2) are important nitrogen and sulfur-containing seven-membered heterocyclic compounds in drug research since they possess diverse bioactivities.^[7-14] 1,5-Benzothiazepines are the most well-known representatives of benzologs of 1,4-thiazepine (3) and one of the three possible benzo-condensed derivatives, viz. 1,4-(4), 4,1- (5) and 1,5-benzothiazepines.^[15-18]

The 1,5-benzothiazepine derivatives are of particular interest for lead discovery because they have been found active against different families of targets.^[19-24] The first molecule of 1,5-benzothiazepine used clinically was diltiazem (6), followed by clentiazem (7), for their cardiovascular action. Some of the 1,5-benzothiazepine derivatives were also used clinically for CNS disorders (8), clothiapine (9) and quetiapine (10). Therefore, the 1,5-benzothiazepines are useful compounds in the drug research which has stimulated the invention of a wide range of synthetic methods for their preparation and chemical transformations.^[25-45]




General structures of 1,5-benzothiazepine





The importance of the 1,5-benzothiazepine nucleus has been well established as illustrated by a large number of compounds which have been patented as chemotherapeutic agents.^[46] A number of biological activities have been associated with it, such as antifeedant,^[47] coronary vasodilatory,^[48] tranquilizer,^[49] antidepressant,^[50] CNS stimulant,^[51] antihypertensive,^[52] calcium channel blocker,^[53] antiulcer,^[54] calcium antagonist,^[55] antimicrobial^[56] and anticonvulsant agents^[57] 1,5-Benzothiazepine molecules have been found to be useful in mucosal blood flow, as antiulcer

Chemical Reaction



Chalcone derivative.

2-Aminothiophenol.
Scheme 12

Benzothiazepine derivative.

and gastric secretion inhibitor. Recently, anticancer activities,^[58] hemodynamic effects,^[59] and spasmolytic activities^[60] have also been reported.

Keeping this broad spectrum of biological activities in mind, in the present investigation it has been considered worthwhile to synthesize benzothiazepines from chalcones derivatives. The compounds were characterized by H^1 NMR and IR analysis. The compounds were tested for their antimicrobial activity by standard protocols.

Experimental work:^[61-62]


Scheme of Synthesis











Synthesis of benzothiazepines from chalcones obtained from 2,4-difluoroacetophenone (Scheme- 12)

General procedure for the synthesis of benzothiazepines

To a solution of chalcone derivative in dry acidic methanol acidified by adding few drops of glacial acetic acid to it, 2-aminothiophenol was added. The mixture was then refluxed until a crystalline solid separates out. After cooling, the solid product was collected and washed with diethylether and cold methanol. The crude solid was recrystallized from ethanol.

Table 1: Physical characterization data of benzothiazepines (BP₁-BP₆).



Compound	R	Molecular Formula	Relative Molecular Mass (RMM)	Melting Point (°C)	Yield %
BP ₁		C ₂₂ H ₁₆ F ₂ N ₂ O ₂ S	410	176-179	94
BP ₂		C ₂₄ H ₂₁ F ₂ NO ₃ S	441	148-151	85
BP ₃		C ₂₂ H ₁₅ F ₂ NO ₂ S	395	156-157	74
BP ₄		C ₁₉ H ₁₂ BrF ₂ NOS	420	132-135	79
BP ₅		C ₂₃ H ₂₀ F ₂ N ₂ S	394	114-117	88
BP ₆		C ₂₂ H ₁₇ F ₂ NO ₂ S	397	151-154	86
BP ₇		C ₂₀ H ₁₄ F ₂ N ₂ S	352	111-114	78
BP ₈		C ₂₀ H ₁₄ F ₂ N ₂ S	352	120-121	82
BP ₉		C ₂₀ H ₁₄ F ₂ N ₂ S	352	110-101	92
BP ₁₀		C ₁₉ H ₁₃ F ₂ NS ₂	357	146-149	86

Spectral data for synthesised 1,5 benzothiazepines: B₁-B₁₀

2,3-Dihydro-2-(3-nitro-4-methylphenyl)-4-(2,4-difluorophenyl)-1,5-benzothiazepine (BP₁₁)

IR (KBr) (cm⁻¹): 1642 (C=N), 1548 (N=O, asymmetric), 1510 (C=C), 1380 (C-N), 1338 (N=O, symmetric), 927 (C-F) and 668 (C-S). ¹H-NMR (CDCl₃) ppm: 4.16 (dd, *J*_{2,3a} = 5.1 Hz, *J*_{2,3b} = 12 Hz, 1H, C₂-H), 3.23 (dd, *J*_{3a,3b} = 14.4 Hz, *J*_{3a,2} = 9.9 Hz, 1H, C₃-H-3a), 2.53 (t, *J*_{3b,3a} = *J*_{3b,2} = 12.9 Hz, 1H, C₃-H-3b), 2.50 (3H, s, Ar-CH₃), 7.30 (1H, s, Ar-H), 6.70 (3H, m, Ar-H), 7.45-8.78 (6, Ar-H).

2,3-Dihydro-2-(3,4,5-trimethoxyphenyl)-4-(2,4-difluorophenyl)-1,5-benzothiazepine (BP₁₂)

IR (KBr) (cm⁻¹): 1648 (C=N), 1505 (C=C), 1365 (C-N), 1225 (-O-CH₃), 923 (C-F) and 678 (C-S). ¹H-NMR (CDCl₃) ppm: 3.06 (dd, *J*_{2,3a} = 5.3 Hz, *J*_{2,3b} = 12 Hz, 1H, C₂-H), 2.83 (dd, *J*_{3a,3b} = 14.4 Hz, *J*_{3a,2} = 9.9 Hz, 1H, C₃-H-3a), 2.0 (t, *J*_{3b,3a} = *J*_{3b,2} = 12.9 Hz, 1H, C₃-H-3b), 7.22 (1H, s, Ar-H), 6.60 (3H, m, Ar-H), 7.30-7.50 (5H, Ar-H), 3.70 (3H, s, Ar-OCH₃), 3.88 (6H, s, 2Ar-OCH₃).

2,3-Dihydro-2-(3,4-methylenedioxyphenyl)-4-(2,4-difluorophenyl)-1,5-benzothiazepine (BP₁₃)

IR (KBr) (cm⁻¹): 1592 (C=N), 1502 (C=C), 1370 (C-N), 1232 (-O-CH₂-O-), 921 (C-F) and 689 (C-S). ¹H-NMR (CDCl₃) ppm: 4.94 (dd, *J*_{2,3a} = 5.1 Hz, *J*_{2,3b} = 12 Hz, 1H, C₂-H), 3.25 (dd, *J*_{3a,3b} = 14.4 Hz, *J*_{3a,2} = 9.1 Hz, 1H, C₃-H-3a), 3.14 (t, *J*_{3b,3a} = *J*_{3b,2} = 12.9 Hz, 1H, C₃-H-3b), 7.25

(1H, s, Ar-H), 7.40 (3H, m, Ar-H), 6.10 (2H, s, O-CH₂-O), 7.21-7.85 (6H, Ar-H).

2,3-Dihydro-2-(5-bromofuran-2-yl)-4-(2,4-difluorophenyl)-1,5-benzothiazepine (BP₁₄)

IR (KBr) (cm⁻¹): 1602 (C=N), 1505 (C=C), 1340 (C-N), 664 (C-S), 933 (C-F) and 790 (C-Br). ¹H-NMR (CDCl₃) ppm: 5.07 (dd, *J*_{2,3a} = 5.3 Hz, *J*_{2,3b} = 12 Hz, 1H, C₂-H), 4.10 (dd, *J*_{3a,3b} = 14.4 Hz, *J*_{3a,2} = 9.2 Hz, 1H, C₃-H-3a), 3.39 (t, *J*_{3b,3a} = *J*_{3b,2} = 12.9 Hz, 1H, C₃-H-3b), 7.10 (1H, s, Ar-H), 6.80 (3H, m, Ar-H), 6.80-7.30 (5H, Ar-H).

2,3-Dihydro-2-(4-dimethylaminophenyl)-4-(2,4-difluorophenyl)-1,5-benzothiazepine (BP₁₅)

IR (KBr) (cm⁻¹): 1608 (C=N), 1509 (C=C), 1390 (C-N), 1175 (-N-(CH₃)₂), 933 (C-F) and 679 (C-S). ¹H-NMR (CDCl₃) ppm: 4.96 (dd, *J*_{2,3a} = 5.3 Hz, *J*_{2,3b} = 12 Hz, 1H, C₂-H), 3.83 (dd, *J*_{3a,3b} = 14.4 Hz, *J*_{3a,2} = 9.2 Hz, 1H, C₃-H-3a), 3.26 (t, *J*_{3b,3a} = *J*_{3b,2} = 12.9 Hz, 1H, C₃-H-3b), 3.20 (6H, s, N-(CH₃)₂), 7.20 (1H, s, Ar-H), 7.45 (3H, m, Ar-H), 6.70-8.20 (7H, Ar-H).

2,3-Dihydro-2-(3-methoxy-4-hydroxyphenyl)-4-(2,4-difluorophenyl)-1,5-benzothiazepine (BP₁₆)

IR (KBr) (cm⁻¹): 3540 (O-H), 1598 (C=N), 1502 (C=C), 1378 (C-N), 1234 (-O-CH₃) 913 (C-F), and 688 (C-S). ¹H-NMR (CDCl₃) ppm: 3.43 (dd, *J*_{2,3a} = 5.1 Hz, *J*_{2,3b} = 12 Hz, 1H, C₂-H), 2.50 (dd, *J*_{3a,3b} = 14.4 Hz, *J*_{3a,2} = 9.4 Hz, 1H, C₃-H-3a), 1.03 (t, *J*_{3b,3a} = *J*_{3b,2} = 12.9 Hz, 1H, C₃-

H-3b), 7.20 (1H, s, Ar-H), 6.85 (3H, m, Ar-H), 7.15-7.90 (6H, Ar-H), 6.95 (1H, s, Ar-OH), 3.80 (3H, s, Ar-O-CH₃).

2,3-Dihydro-2-(2-pyridinyl)-4-(2,4-difluorophenyl)-1,5-benzothiazepine (BP₁₇)

IR (KBr) (cm⁻¹): 1602 (C=N), 1510 (C=C), 1390 (C-N), 924 (C-F) and 677 (C-S); ¹H-NMR (CDCl₃) ppm: 4.91 (dd, *J*_{2,3a} = 5.3 Hz, *J*_{2,3b} = 12 Hz, 1H, C₂-H), 3.44 (dd, *J*_{3a,3b} = 14.4 Hz, *J*_{3a,2} = 9.4 Hz, 1H, C₃-H-3a), 1.05 (t, *J*_{3b,3a} = *J*_{3b,2} = 12.9 Hz, 1H, C₃-H-3b), 7.15 (1H, s, Ar-H), 7.20 (3H, m, Ar-H), 7.10-8.15 (7H, Ar-H).

2,3-Dihydro-2-(3-pyridinyl)-4-(2,4-difluorophenyl)-1,5-benzothiazepine (BP₁₈)

IR (KBr) (cm⁻¹): 1599 (C=N), 1506 (C=C), 1382 (C-N), 927 (C-F) and 698 (C-S); ¹H-NMR (CDCl₃) ppm: 4.38 (dd, *J*_{2,3a} = 5.3 Hz, *J*_{2,3b} = 12 Hz, 1H, C₂-H), 3.37 (dd, *J*_{3a,3b} = 14.4 Hz, *J*_{3a,2} = 9.8 Hz, 1H, C₃-H-3a), 1.07 (t, *J*_{3b,3a} = *J*_{3b,2} = 12.9 Hz, 1H, C₃-H-3b), 7.25 (1H, s, Ar-H), 7.30 (3H, m, Ar-H), 6.75-8.90 (7H, Ar-H).

2,3-Dihydro-2-(4-pyridinyl)-4-(2,4-difluorophenyl)-1,5-benzothiazepine (BP₁₉)

IR (KBr) (cm⁻¹): 1606 (C=N), 1508 (C=C), 1388 (C-N), 933 (C-F) and 654 (C-S); ¹H-NMR (CDCl₃) ppm: 4.67 (dd, *J*_{2,3a} = 5.1 Hz, *J*_{2,3b} = 12 Hz, 1H, C₂-H), 3.42 (dd, *J*_{3a,3b} = 14.4 Hz, *J*_{3a,2} = 9.8 Hz, 1H, C₃-H-3a), 2.50 (t, *J*_{3b,3a} = *J*_{3b,2} = 12.9 Hz, 1H, C₃-H-3b), 7.20 (1H, s, Ar-H), 7.50 (3H, m, Ar-H), 6.95-8.68 (7H, Ar-H).

2,3-Dihydro-2-(2-thienyl)-4-(2,4-difluorophenyl)-1,5-benzothiazepine (BP₂₀)

IR (KBr) (cm⁻¹): 1605 (C=N), 1503 (C=C), 1386 (C-N), 928 (C-F) and 644 (C-S); ¹H-NMR (CDCl₃) ppm: 5.50 (dd, *J*_{2,3a} = 5.3 Hz, *J*_{2,3b} = 12 Hz, 1H, C₂-H), 3.53 (dd, *J*_{3a,3b} = 14.4 Hz, *J*_{3a,2} = 9.9 Hz, 1H, C₃-H-3a), 2.90 (t, *J*_{3b,3a} = *J*_{3b,2} = 12.9 Hz, 1H, C₃-H-3b), 7.20 (1H, s, Ar-H), 7.34 (3H, m, Ar-H), 6.60-7.80 (6H, Ar-H).

Biological evolution 62

Antioxidant activity by DPPH method (8)

Antioxidant behavior of these chalcones and pyrimidines derivatives were measured *in vitro* by the inhibition of generated stable 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical. Methods vary greatly as to the generated radical, the reproducibility of the generation process, and the end point that is used for the determination. The DPPH solution was prepared by dissolving accurately weighed 22 mg of DPPH in 100 ml of ethanol. From this stock solution, 18 ml was diluted to 100 ml with ethanol to obtain 100 μM DPPH solutions. The sample solution was prepared by accurately weighed 2.1 mg of each of the compounds and dissolved in 1 ml of freshly distilled DMSO separately to obtain solutions of 2.1 mg/ml concentration and the standard solution of was prepared by accurately weighed 10.5 mg of α-Tocopherol and dissolved in 1 ml of freshly distilled DMSO to get 10.5 mg/ml concentration.

A solution of test compound in ethanol (500 μl) was added to the ethanolic solution of DPPH radical. The reaction mixture was vortexed thoroughly and left in the dark at room temperature for 30 min. The absorbance of the mixture was measured spectrophotometrically at 517 nm against the corresponding blank solution. The final concentration of the samples and standard Ascorbic acid solutions used is 100 μg/ml. The percentage scavenging DPPH radical inhibitions were calculated by using the following formula:


$$\text{DPPH radical scavenging activity (\%)} = \frac{(\text{Abs control} - \text{Abs sample})}{\text{Abs control}} \times 100$$

Where, Abs control was the absorbance of DPPH radical and ethanol, Abs sample was the absorbance of DPPH radical and sample/standard.

The scavenging activity was expressed in terms of IC₅₀, the concentration of the samples required to give a 50% reduction in the intensity of the signal of the DPPH radical. The results were done at least in triplicate.

RESULTS AND DISCUSSION

Table 2: Antibacterial activity of synthesised compounds (BP₁ to BP₁₀).
(Expressed as MIC in μg/mL)



Compound	R	Antioxidant activity (%inhibition)
B ₁	3''-nitro-4''-methylphenyl	66
B ₂	3'',4'',5''-trimethoxyphenyl	54
B ₃	3'',4''-methylendioxyphenyl	68
B ₄	5''-bromofuran-2''-yl	90
B ₅	4''-dimethylaminophenyl	64
B ₆	3''-methoxy-4''-hydroxyphenyl	60
B ₇	2''-pyridinyl	74
B ₈	3''-pyridinyl	80
B ₉	4''-pyridinyl	84
B ₁₀	2''-thienyl	86
Standard (Ascorbic acid)		48

DISCUSSION

1,5 benzothiazepines were designed synthesized by the condensation 1,3-diphenyl-2-propene-1-one with 2-aminothiophenol in presence of glacial acetic acid to form cyclic product . The obtained compound structures were characterized by its IR and ¹H NMR spectral data. Based on the values the compounds 1,5 benzothiazepines were shows better activity Here the compound contains the electron with drawing along the electron releasing groups maximum anti oxidant activity than the other molecule here compound B₂ (2,3-Dihydro-2-(3,4,5-trimethoxyphenyl)-4-(2,4-difluorophenyl)-1,5-benzothiazepine) show activity along with standard ascorbic acid.

CONCLUSION

From the above results it is evident that synthesized chalcone derivatives and di hydro 1,5 benzothiazepines derivatives showed significant in vitro anti oxidant activity. In particularly, compounds containing the electron releasing groups (like OCH₃, OH) show the maximal antioxidant activity compare with standard compound ascorbic acid

ACKNOWLEDGEMENT

We are grateful to QIS college of Pharmacy Management and principal for providing necessary research facilities and guidance to carry out our work.

REFERENCES

- Anshu, D, Ruby, S, Dharmendra S, Ashok, L Asha, S. et al. Regioselective Synthesis of Diltiazem Analogue Pyrazolo[4,3-c][1,5]benzothiazepines and Antifungus Activity, Phosphorus, Sulfur, Silicon Relat. Elem., 2010; 185: 2472-2479.
- Ghotekar, D.S., Joshi, R.S., Mandhane, P.G., Bhagat, S.S., Gill, C.H. Indian J. Chem., Sect. B, 2010; 49B: 1267.
- Pant, S, Sharma, P., Pant, U.C. Syntheses of 1,5-Benzothiazepines: Part XXXVI—Syntheses and Antiminium Inhibitory Concentrationrobial Evaluation of 2-(2-Chlorophenyl)-4-(4-chlorophenyl/2-thienyl)-2,5-dihydro-8-substituted-1,5-benzothiazepines , Phosphorus, Sulfur, Silicon Relat. Elem., 2008; 183: 2974-2983.
- Desai, K.G., Desai, K.R. minium Inhibitory Concentrationrowave enhanced heterocyclization: a convenient procedure for anitminium Inhibitory Concentrationrobial 1,5 benzothiazepines. Indian J. Chem., Sect. B, 2007; 46B: 1179-1186.
- Garg, N., Chandra, T., Archana; Jain, A.B., Kumar, A. Synthesis and evaluation of some new substituted benzothiazepine and benzoxazepine derivatives as anticonvulsant agents Eur. J. Med. Chem, 2010; 45: 1529-1535.
- Sarro, G.D., Chimirri, A., Sarro, A.D., Gitto, R., Grasso, S., Zappala, M., 5H-[1,2,4]Oxadiazolo[5,4-d][1,5]benzothiazepines as anticonvulsant agents in DBA/2 minium Inhibitory ConcentrationEur. J. Med. Chem., 1995; 30: 925-929.
- Saini, R.K., Joshi, Y.C., Joshi, P. Phosphorus, Sulfur, Silicon Relat. Elem, 2008; 183: 2181.
- Grandolini, G., Perioli, L., Ambrogi, V., Syntheses of 1,5-Benzothiazepines: Part XXXVI—Syntheses and Antiminium Inhibitory Concentrationrobial Evaluation of 2-(2-Chlorophenyl)-4-(4-chlorophenyl/2-thienyl)-2,5-dihydro-8-substituted-1,5-benzothiazepines , Eur. J. Med. Chem, 1999; 34: 701-709.
- Yamada, S., Mori, Y., Morimatsu, K., Ishizu, Y., Ozaki, Y., Yoshioka, R., Nakatani, T., Seko, H. J. Org. Chem., 1996; 61: 8586.
- Maayan, S., Ohad, N. and Soliman, K., Chalcones as potent tyrosinase inhibitors: the importance of a 2,4-substituted resorcinol moiety, *Bioorg. Med. Chem.*, 2005; 13: 433-441.
- Nowakowska, A review of anti-infective and anti-inflammatory chalcones, *Eur. J. Med. Chem*, 2007; 4: 125-137.
- Go, M.L., Wu, X. and Liu, X.L., Chalcones: An Update on Cytotoxic and Chemoprotective Properties, *Current Medicinal Chemistry*, 2005; 12(4): 483-499.
- Mark, C. and Nagarathnam, D., Cytotoxicities of some flavonoid analogues, *J. Nat. Prod.* 1991; 54: 1656-1660.
- Wilson, C. W., *J.Asian chem. Soc*, 1938; 61: 2303-2309.
- Claisen, L. and Claparede, A., *Ber*, 1881; 14: 2463-2371.
- Datta, S.C., Murthi, V.V.S. and Seshadri, T.R., *Ind. J. Chem*, 1971; 9: 614-621.
- Makrandi J K, Shashi, S Kumar, An Efficient Synthesis of 2'- Hydroxichalcones. *Asian J Chem*, 2004; 16(2): 1189- 1190.
- Reichel, L. and Muller, K., *Ber*, 1941; 74: 1741-1752.
- Saravanamurugan, S., Palanichamy, M. and Banumathi, A., *Catalysis Comm*, 2005; 6: 399-406.
- Anjaneyulu, A.S.R., Sudha Rani, G., Mallavadhani, U.V. and Murthy, Y.L.N., *Ind. J. Het. Chem*, 1994; 4: 9-21.
- Bala Krishna, K. and Ganesha Rani. Environmentally benign reaction: synthesis of syndrone chaclone under solvent free conditions, *Ind. J. Chem*, 2003; 42B: 2556-2557.
- Deshpande, Anil M., et al. "Synthesis and screening of a combinatorial library of naphthalene substituted chalcones: inhibitors of leukotriene B 4." *Bioorganic & medicinal chemistry*, 1999; 7(6): 1237-1240.
- Baaterham, T.J. and Highet, R.J. Nuclear magnetic resonance spectra of flavonoids, *Australian J.Chem*, 1964; 17: 428 -436.
- Hegert, H.L. and Kurth, E.F., *J. Am. Chem. Soc.*, 1953; 75: 1622-1630.
- Kurokawa, J., Adachi-Akahane, S., Nagao, T. *Eur. J. Pharmacol*, 1977; 325: 229-229.

26. Urbanski, M.J., Chen, R.H., Demarest, K.T., Gunnet, J., Look, R., Ericson, E., Murray, W.V., Rybczynski, P.J., Zhang, X. *Bioorg. Med. Chem. Lett*, 2003; 13: 4031-4040.
27. Di Santo, R., Costi, R. *Farmaco*, 2005; 60: 385-390.
28. Kumar, A., Ahmad, I., Sudershan Rao, M. *J Sulfur Chem*, 2009; 30: 570-578.
29. Hekmatshoar, R., Sadjadi, S., Shiri, S., Heravi, M.M., Beheshtiha, Y.S. *Synth. Commun*, 2009; 39: 2549-2556.
30. Pan, X.-Q., Zou, J.-P., Huang, Z.-H., Zhang, W. et al. *Tetrahedron Lett*, 2008; 49: 5302-5306.
31. Sharma, G., Kumar, R., Chakraborti, A.K. *Tetrahedron Lett*, 2008; 49: 4272-4285.
32. Sharma, G., Kumar, R., Chakraborti, A.K. *Tetrahedron Lett.*, 2008; 49: 4269.
33. Khatik, G.L., Kumar, R., Chakraborti, A.K. *Synthesis*, 2007; 4: 541-550.
34. Khatik, G.L., Sharma, G., Kumar, R., Chakraborti, A.K. *Tetrahedron*, 2006; 63: 1200-1212.
35. Chen, X., Zhong, W., Zhang, Y. *J. Chem. Res. (S)*, 2000; 24: 386-394.
36. Orlov, V.D., Kolos, N., Ruzhitskaya, N.N. *Khim. Geterotsikl. Soedin*, 1985; 12: 1638 -1644.
37. Yang, C.G., Fang, L.Z., Wu, L.Q., Yan, F.L. *Asian J. Chem*, 2010; 22: 6031-6340.
38. Sharma, G.V.M., Reddy, J.J., Lakshmi, P.S., Krishna, P.R. *Tetrahedron Lett*, 2004; 45: 7729-7765.
39. Wu, L.Q., Yang, X.J., Wang, X., Yan, F.L. *J. Sulfur Chem*, 2010; 31: 509 -514.
40. Bigdeli, M.A., Heravi, M.M., Mahdavinia, G.H. *Catal. Commun*, 2007; 8: 1595-1605.
41. Rahman, M., Roy, A., Majee, A., Hajra, A. *J. Chem. Res.* 2009; 33: 178-179.
42. L. H. Sternbach, *Prog. Drug Res*, 1978; 22: 229-235.
43. G. Roma, G. C. Grossi, B. M. Di, M. Ghia, and F. Mattioli, *Eur. J. Med. Chem*, 1991; 25: 489-495.
44. J. X. Xu and S. Jin, *Heteroatom Chem*, 1999; 10: 35-42.
45. J. Xu, and Z. Gang, *Rapid Communication in Mass Spectrometry*, 2000; 14: 2373.
46. Opera T. I., Davis A. M., and Teague S. J., *J. Chem. Inf. Comput. Sci.*, 2001; 71(41): 1308
47. Hagiwara M., Adachi S., and Nagao T., *Pharmacology and Experimental Therapeutics*, 1997; 281(1): 173.
48. Liegeois J. F., Bruliwyler J., and Rogister F., *Curr. Med. Chem*, 1995; 6: 471.
49. Ishikawa, H., Matsushima, M., Matsui, H., Honjo, A., Hayashi, M., Shindo, T., Morifuji, T., Okaybayashi, M. *Arzneim.-Forsch*, 1978; 28: 402.
50. Zobrist, R.H., Mecca, T.E. *Pharmacol. Exp. Ther*, 1990; 253: 461.
51. Murata, S., Kikawa, K., Iwasaki, H.O., Toriumi, W., Nagoa, T., *Eur. J. Pharmacol*, 1990; 183: 1070.
52. Kaburaki, M., Inoue, H., Doi, H., Yasuhara, M., Narita, H., *Biol. Pharm. Bull*, 1998; 21: 50.
53. Kaburaki, M., Yabana, H., Doi, H., Nagata, K., Narita, H., Murata, S. *J. Pharmacol. Exp. Ther*, 1999; 288: 1167.
54. Doi, H., Kaburaki, M., Inoue, H., Suzumura, K., Narita, H. *J. Pharmacol*, 2000; 83: 73.
55. Atwal, S.Z., Ahmed, D.M., Floyd, S., Moreland, A., Hedberg, *Bioorg. Med. Chem. Lett*, 1993; 3: 2797.
56. Masui, M., Funakawa, S., Uno, O., Mihara, S., Takahara, Y., Matsunaga, K., Iwaki, K. *Cardiovasc. Pharmacol*, 1996; 28: 526.
57. Kawakami, M., Matsumura, S., Shimamura, T., Iwasaki, T., Furukawa, H., Matsunaga, K., Yonetani, Y., Iwaki, K., *J. Cardiovasc. Pharmacol*, 1996; 28: 695.
58. Kimoto, S., Haruna, M., Matsuura, E., Uno, O., Ishii, M., Hirono, S., Yoshimura, K., Ueda, M., Iwaki, K., *J. Cardiovasc. Pharmacol*, 1997; 29: 180.
59. Kurokawa, J., Adachi-Akahane, S., Nagao, T. *Eur. J. Pharmacol*, 1997; 325: 229.
60. Hagiwara, M., Adachi-Akahane, S., Nagao, T. *J. Pharmacol. Exp. Ther*, 1997; 281: 173.
61. CH.M.M.Prasada Rao, Rahaman S.A, Rajendra Prasad Yejella., *World Journal of Pharmacy and Pharmaceutical Sciences*, 2014; 3(11): 576-578.
62. Ch. M. M. Prasad Rao, " Docking, Synthesis And Evaluation Of Antioxidant Activity Of 9-(Piperazin-1-Yl) Acridine Derivatives From 2-[(4-Methyl-2- Nitrophenyl) Amino]Benzoic Acid" *ejbps*, 2017; 4(05): 514-522.